Â鶹ŮÓÅ

Hundreds of thousands of Americans stand to soon lose their access to cheaper weight-loss drugs, with a federal crackdown on copycat versions threatening to disrupt treatment and raise costs. The Food and Drug Administration has ordered producers and sellers of the less expensive products to wind down operations in the coming weeks now that it has declared there are no longer shortages of the blockbuster drugs Wegovy and Zepbound. (Robbins and Blum, 4/16)

A daily pill may be as effective in lowering blood sugar and aiding weight loss in people with Type 2 diabetes as the popular injectable drugs Mounjaro and Ozempic, according to results of a clinical trial announced by Eli Lilly on Thursday morning. (Kolata, 4/17)

If orforglipron is eventually approved by federal regulators, it would become the first GLP-1 oral drug for weight loss to hit the market. The implications—if Lilly’s drug makes it through the testing and review process—could be transformative, not just for the company, but for patients. (Park, 4/17)

Semler Scientific has offered to pay the Department of Justice nearly $30 million to settle federal health care fraud claims related to its peripheral artery disease test, QuantaFlo — a product used by UnitedHealth Group and other large insurers. (Lawrence, 4/16)

RadNet, which runs nearly 400 radiology imaging centers in the United States, wants to put artificial intelligence into breast imaging. Over the last five years, the company has moved aggressively to expand its AI capabilities, deploying the technology for breast cancer screenings at its radiology practices. (Palmer, 4/17)

Limiting the use of personal protective equipment (PPE) to only N95 respirators late in the COVID-19 pandemic in Singapore healthcare facilities kept staff safe, reduced plastic waste and carbon emissions, and lowered related costs, a JAMA Network Open study concludes. (Van Beusekom, 4/16)

European regulators have finally approved the Alzheimer’s treatment Leqembi after an advisory committee initially rejected the drug last summer and then reconsidered it. The infused treatment from Japanese drugmaker Eisai and Biogen received approval for patients in early stages of the fatal, mind-robbing disease. The decision applies to all 27 members of the European Union plus Norway, Iceland and Liechtenstein, the drugmakers said late Tuesday. (Murphy, 4/16)

Climate change and increasingly extreme weather are taking a toll on global supplies of blood, endangering the lives of people with life-threatening injuries and conditions, a new study has found. Extreme weather events and natural disasters such as bushfires and floods, fueled by rising global temperatures, are disrupting medical professionals in their efforts to collect, testing, transport and store blood, according to a study published in The Lancet Planetary Health this week. (Kan, 4/17)